Möbest D, Goan S R, Junghahn I, Winkler J, Fichtner I, Hermann M, Becker M, de Lima-Hahn E, Henschler R
Experimental Hematology Group, Department of Hematology/Oncology, University Medical Center, Freiburg, Germany.
Stem Cells. 1999;17(3):152-61. doi: 10.1002/stem.170152.
So far, blood progenitor cells (BPC) expanded ex vivo in the absence of stromal cells have not been demonstrated to reconstitute hematopoiesis in myeloablated patients. To characterize the fate of early hematopoietic progenitor cells during ex vivo expansion in suspension culture, human CD34(+)-enriched BPC were cultured in serum-free medium in the presence of FLT3 ligand (FL), stem cell factor (SCF) and interleukin 3 (IL-3). Both CD34 surface expression levels and the percentage of CD34+ cells were continuously downregulated during the culture period. We observed an expansion of colony-forming units granulocyte-macrophage (CFU-GM) and BFU-E beginning on day 3 of culture, reaching an approximate 2-log increase by days 5 to 7. Limiting dilution analysis of primitive in vitro clonogenic progenitors was performed through a week 6 cobblestone-area-forming cell (CAFC) assay, which has previously been shown to detect long-term bone marrow culture-initiating cells (LTC-IC). A maintenance or a slight (threefold) increase of week 6 CAFC/LTC-IC was found after one week of culture. To analyze the presence of BPC mediating in vivo engraftment, expanded CD34+ cells were transplanted into preirradiated NOD/SCID mice at various time points. Only CD34+ cells cultured for up to four days successfully engrafted murine bone marrow with human cells expressing myeloid or lymphoid progenitor phenotypes. In contrast, five- and seven-day expanded human BPC did not detectably engraft NOD/SCID mice. When FL, SCF and IL-3-supplemented cultures were performed for seven days on fibronectin-coated plastic, or when IL-3 was replaced by thrombopoietin, colony forming cells and LTC-IC reached levels similar to those of control cultures, yet no human cell engraftment was recorded in the mice. Also, culture in U-bottom microplates resulting in locally increased CD34+ cell density had no positive effect on engraftment. These results indicate that during ex vivo expansion of human CD34+ cells, CFC and LTC-IC numbers do not correlate with the potential to repopulate NOD/SCID mice. Our results suggest that ex vivo expanded BPC should be cultured for limited time periods only, in order to preserve bone-marrow-repopulating hematopoietic stem cells.
到目前为止,在无基质细胞条件下体外扩增的血液祖细胞(BPC)尚未被证明能在接受清髓治疗的患者中重建造血功能。为了描述早期造血祖细胞在悬浮培养体外扩增过程中的命运,将富集人CD34(+)的BPC在含有FLT3配体(FL)、干细胞因子(SCF)和白细胞介素3(IL-3)的无血清培养基中培养。在培养期间,CD34表面表达水平和CD34+细胞百分比均持续下调。我们观察到粒细胞-巨噬细胞集落形成单位(CFU-GM)和爆式红系集落形成单位(BFU-E)从培养第3天开始扩增,到第5至7天增加了约2个对数。通过第6周鹅卵石区形成细胞(CAFC)试验对原始体外克隆形成祖细胞进行有限稀释分析,该试验先前已被证明可检测长期骨髓培养起始细胞(LTC-IC)。培养一周后,发现第6周CAFC/LTC-IC维持不变或略有增加(三倍)。为了分析介导体内植入的BPC的存在情况,在不同时间点将扩增的CD34+细胞移植到经预照射的NOD/SCID小鼠体内。只有培养至4天的CD34+细胞成功植入小鼠骨髓,植入的人细胞表达髓系或淋巴系祖细胞表型。相比之下,培养5天和7天的人BPC未在NOD/SCID小鼠中检测到明显植入。当在纤连蛋白包被的塑料上进行添加FL、SCF和IL-3的培养7天,或者用血小板生成素替代IL-3时,集落形成细胞和LTC-IC达到与对照培养相似的水平,但在小鼠中未记录到人类细胞植入。此外,在U型微孔板中培养导致局部CD34+细胞密度增加,对植入没有积极影响。这些结果表明,在人CD34+细胞的体外扩增过程中,CFC和LTC-IC数量与重建NOD/SCID小鼠造血功能的潜力无关。我们的结果表明,体外扩增的BPC应仅在有限的时间段内培养,以保留具有骨髓重建能力的造血干细胞。